C Olanow

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study
    Fabrizio Stocchi
    Institute of Neurology, IRCCS Neuromed, Pozzilli Is, Italy
    Arch Neurol 62:905-10. 2005
  2. ncbi request reprint Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neurology 66:S69-79. 2006
  3. doi request reprint Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY, USA Electronic address
    Lancet Neurol 13:141-9. 2014
  4. doi request reprint Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 28:31-40. 2013
  5. doi request reprint Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Mov Disord 24:336-43. 2009
  6. ncbi request reprint A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Ann Neurol 54:403-14. 2003
  7. doi request reprint Levodopa/dopamine replacement strategies in Parkinson's disease--future directions
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
    Mov Disord 23:S613-22. 2008
  8. ncbi request reprint Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:677-87. 2006
  9. doi request reprint The pathogenesis of cell death in Parkinson's disease--2007
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 22:S335-42. 2007
  10. ncbi request reprint Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
    C W Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Neurol 61:1563-8. 2004

Research Grants

Detail Information

Publications80

  1. ncbi request reprint Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study
    Fabrizio Stocchi
    Institute of Neurology, IRCCS Neuromed, Pozzilli Is, Italy
    Arch Neurol 62:905-10. 2005
    ..Motor complications can be diminished with a continuous infusion of levodopa...
  2. ncbi request reprint Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neurology 66:S69-79. 2006
    ..These results argue against the benefit being due to a symptomatic effect and are consistent with rasagiline having a protective effect...
  3. doi request reprint Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY, USA Electronic address
    Lancet Neurol 13:141-9. 2014
    ..We aimed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through an intrajejunal percutaneous tube...
  4. doi request reprint Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 28:31-40. 2013
    ..We propose that this mechanism plays an important role in the development of PD and provides novel targets for candidate neuroprotective therapies...
  5. doi request reprint Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Mov Disord 24:336-43. 2009
    ..Off-medication dyskinesias are common following transplantation and may represent a prolonged form of diphasic dyskinesias...
  6. ncbi request reprint A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Ann Neurol 54:403-14. 2003
    ..Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on these results...
  7. doi request reprint Levodopa/dopamine replacement strategies in Parkinson's disease--future directions
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
    Mov Disord 23:S613-22. 2008
    ..However, problems of continuous dopaminergic stimulation must be addressed and avoided, and the issue of nondopaminergic features remains to be addressed...
  8. ncbi request reprint Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:677-87. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides clinical benefits but avoids motor complications...
  9. doi request reprint The pathogenesis of cell death in Parkinson's disease--2007
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 22:S335-42. 2007
    ..It is anticipated that over the next few years there will be a flurry of scientific activity examining the mechanism of cell death and putative neuroprotective interventions...
  10. ncbi request reprint Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
    C W Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Neurol 61:1563-8. 2004
    ....
  11. ncbi request reprint Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions
    Anthony H V Schapira
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, and Institute of Neurology, Queen Square, London, England
    JAMA 291:358-64. 2004
    ..We review clinical trials aimed at detecting neuroprotection in Parkinson disease and address the controversies surrounding the interpretation of these studies...
  12. ncbi request reprint The scientific basis for the current treatment of Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, Box 1137, New York, New York 10029, USA
    Annu Rev Med 55:41-60. 2004
    ..No drug has yet been established to alter the rate of disease progression, but the rapid pace of research offers reason for optimism...
  13. ncbi request reprint Tolcapone: an efficacy and safety review (2007)
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, USA
    Clin Neuropharmacol 30:287-94. 2007
    ..In addition, patients must be taken off the drug if blood tests show enzyme elevation of greater than twice the upper limit of normal. This article reviews the data pertaining to the safety and efficacy of tolcapone...
  14. ncbi request reprint Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Neurol 2:382-92. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides comparable anti-parkinsonian benefits without motor complications...
  15. ncbi request reprint Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  16. ncbi request reprint Ubiquitin-proteasome system and Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York10029, USA
    Mov Disord 21:1806-23. 2006
    ..It also suggests novel targets for putative neuroprotective therapies for PD...
  17. ncbi request reprint TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:1013-20. 2006
    ..TCH346 is a potent anti-apoptotic drug that protects against loss of dopaminergic neurons in laboratory models. Our aim was to assess TCH346 as a neuroprotective drug in patients with Parkinson's disease...
  18. ncbi request reprint Dietary vitamin E and Parkinson's disease: something to chew on
    C Warren Olanow
    Department of Neurology, Box 1137, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Lancet Neurol 2:74. 2003
  19. doi request reprint A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 23:2194-201. 2008
    ..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial...
  20. ncbi request reprint Movement disorders: a step in the right direction
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
    Lancet Neurol 5:3-5. 2006
  21. doi request reprint Defining disease-modifying therapies for PD--a road map for moving forward
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 25:1774-9. 2010
    ..Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease...
  22. ncbi request reprint Manganese-induced parkinsonism and Parkinson's disease
    C W Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Ann N Y Acad Sci 1012:209-23. 2004
    ..This is of particular relevance in differentiating patients with parkinsonism due to manganese intoxication from patients with idiopathic PD who have incidental manganese exposure...
  23. ncbi request reprint Surgical therapy for Parkinson's disease
    C W Olanow
    Mount Sinai School of Medicine, Department of Neurology, New York, NY 10029, USA
    Eur J Neurol 9:31-9. 2002
    ..Stem cell, trophic factor, and gene therapy approaches are promising and are currently under intensive investigation...
  24. doi request reprint Dopaminergic transplantation for Parkinson's disease: current status and future prospects
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann Neurol 66:591-6. 2009
    ..Collectively, these findings do not bode well for the short-term future of cell-based dopaminergic therapies in PD...
  25. doi request reprint A double-blind, delayed-start trial of rasagiline in Parkinson's disease
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    N Engl J Med 361:1268-78. 2009
    ..A therapy that slows disease progression is the major unmet need in Parkinson's disease...
  26. doi request reprint The scientific and clinical basis for the treatment of Parkinson disease (2009)
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Annenberg 14 94, New York, NY 10029, USA
    Neurology 72:S1-136. 2009
    ..It is intended to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of the different approaches...
  27. doi request reprint Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
    Neurology 72:S59-64. 2009
    ..This article reviews currently available drugs for PD and considers the evidence that they might have neuroprotective effects in PD...
  28. doi request reprint Why have we failed to achieve neuroprotection in Parkinson's disease?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, USA
    Ann Neurol 64:S101-10. 2008
    ..New developments in understanding the cause of the disease, in the development of animal models of PD, and in clinical trial methodology will hopefully hasten the resolution of these problems...
  29. ncbi request reprint Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, New York, NY 10029, USA
    Mov Disord 20:S3-10. 2005
    ..If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa...
  30. ncbi request reprint Lewy-body formation is an aggresome-related process: a hypothesis
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 3:496-503. 2004
    ..The concept of Lewy bodies as aggresome-related inclusions fits well with ongoing discoveries suggesting that altered protein handling might contribute to the neurodegenerative process in familial and sporadic forms of PD...
  31. ncbi request reprint Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann Neurol 53:S73-84; discussion S84-6. 2003
    ..It has also facilitated the development of experimental models that recapitulate the behavioral and pathological features of PD, and hopefully will lead to the development of novel neuroprotective therapies for the disorder...
  32. ncbi request reprint Proteasome inhibition causes nigral degeneration with inclusion bodies in rats
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
    Neuroreport 13:1437-41. 2002
    ..These findings support the notion that failure of the ubiquitin-proteasome system to degrade and clear unwanted proteins is an important etiopathogenic factor in Parkinson's disease...
  33. ncbi request reprint Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  34. ncbi request reprint COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10028, USA
    Neurology 62:S72-81. 2004
    ..This article considers the possibility that combining levodopa with entacapone may prevent or reverse motor complications...
  35. ncbi request reprint Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress
    Venugopalan D Nair
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 279:27494-501. 2004
    ..These studies suggest that the individual cell rapidly and stochastically processes the oxidative stress stimulus, leading to an all-or-none cytoprotective or pro-apoptotic signaling response...
  36. pmc Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines
    Venugopalan D Nair
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Biochem J 373:25-32. 2003
    ..These studies indicate that certain dopamine agonists can complex with D(2) receptors to preferentially transactivate neuroprotective signalling pathways and to mediate increased cell survival...
  37. ncbi request reprint The neuropathology of manganese-induced Parkinsonism
    Daniel P Perl
    Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Neuropathol Exp Neurol 66:675-82. 2007
    ..These pathologic findings do not support the notion that manganese causes PD but rather argues that manganese-induced parkinsonism and PD are distinct and separate disease entities...
  38. ncbi request reprint Proteasomal dysfunction in sporadic Parkinson's disease
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neurology 66:S37-49. 2006
    ..It remains to be established if proteasomal dysfunction plays a primary or a secondary role in the initiation or progression of the neurodegenerative process in PD...
  39. pmc Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait
    Catherine Cho
    Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1135, New York, NY 10029 6574, USA
    J Neurophysiol 103:1478-89. 2010
    ..We postulate that the inability to control step frequency and adjust swing phase dynamics to slower walking velocities are major causes for the gait impairment in PD...
  40. ncbi request reprint p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition
    Venugopalan D Nair
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 281:39550-60. 2006
    ..These results suggest that abnormalities in p53 signaling play a role in dopaminergic cell death induced by proteasome inhibition and may be relevant to neurodegeneration in PD...
  41. pmc Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses
    Venugopalan D Nair
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Biol Chem 283:15469-78. 2008
    ..Inhibition of GSK-3beta activity by inhibitor VIII protects cells from H2O2 similar to ropinirole. These results indicate that GSK-3beta downstream of Akt plays a critical role in cell death and survival in these models...
  42. ncbi request reprint A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulation
    Catherine Cho
    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
    Conf Proc IEEE Eng Med Biol Soc 1:1228-31. 2006
    ..In the present study, we determined whether model parameters were altered in subjects with PD when they were tested on/off levodopa (LD) and on/off deep brain stimulation (DBS) in a 2 x 2 matrix...
  43. ncbi request reprint Prevalence of movement disorders in an elderly nursing home population
    Winona Tse
    Department of Neurology, Mount Sinai Medical Center, One Gustave L Levy Place, Box 1052, New York, NY 10029, USA
    Arch Gerontol Geriatr 46:359-66. 2008
    ..The discrepancy between our findings and the prevalence rates for parkinsonism reported on the initial transfer diagnosis emphasizes the difficulty of accurate diagnosis of movement disorders and in particular parkinsonism...
  44. ncbi request reprint Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
    Neurobiol Aging 27:530-45. 2006
    ..This suggests that manipulation of proteolytic systems is a rational approach in the development of neuroprotective therapies that could modify the pathological course of PD...
  45. ncbi request reprint Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Neurochem 81:301-6. 2002
    ..This study supports the concept that defects in the UPS may underlie nigral pathology in familial and sporadic forms of PD...
  46. ncbi request reprint Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
    Kevin St P McNaught
    Department of Neurology, Neuropathology Division, Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann Neurol 56:149-62. 2004
    ..This animal model induced by proteasome inhibitors closely recapitulates key features of PD and may be valuable in studying etiopathogenic mechanisms and putative neuroprotective therapies for the illness...
  47. ncbi request reprint Overexpression of torsinA in PC12 cells protects against toxicity
    P Shashidharan
    Department of Neurology, Mount Sinai School of Medicine, New York 10029, USA
    J Neurochem 88:1019-25. 2004
    ..Overexpression of mutant torsinA failed to protect cells against trophic withdrawal. These results suggest that torsinA may play a protective role in neurons against a variety of cellular insults...
  48. ncbi request reprint Brainstem pathology in DYT1 primary torsion dystonia
    Kevin St P McNaught
    Department of Neurology, Neuropathology Division, Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann Neurol 56:540-7. 2004
    ..and cuneiform nuclei, and related brainstem brainstem structures, in mediating motor activity and controlling muscle tone suggests that alterations in these structures could underlie the pathophysiology of DYT1 dystonia [corrected]..
  49. ncbi request reprint Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress
    Catherine Mytilineou
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Pharmacol Exp Ther 304:792-800. 2003
    ..This study provides further evidence to support the notion that although levodopa can be toxic to dopamine neurons in vitro, it is not likely to be toxic to dopamine neurons in vivo and specifically in conditions such as PD...
  50. ncbi request reprint Clinical usefulness of the Parkinson's disease sleep scale
    Winona Tse
    Department of Neurology, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Parkinsonism Relat Disord 11:317-21. 2005
    ..To test the usefulness of the Parkinson's disease sleep scale (PDSS) in identifying sleep disorders in the clinical practice setting...
  51. ncbi request reprint Proteasome inhibitor-induced model of Parkinson's disease
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
    Ann Neurol 60:243-7. 2006
    ..We have begun to examine various factors that alone or in combination might explain these differences, and we present in this article preliminary results from these studies...
  52. ncbi request reprint Aggresome-related biogenesis of Lewy bodies
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
    Eur J Neurosci 16:2136-48. 2002
    ..This phenomenon is consistent with growing evidence that altered protein handling underlies the etiopathogenesis of PD and related disorders...
  53. ncbi request reprint Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
    Neurosci Lett 326:155-8. 2002
    ..Thus, structural and function defects in 26/20S proteasomes may underlie protein accumulation, formation of proteinaceous Lewy bodies and dopaminergic neuronal death in the SNc in sporadic PD...
  54. ncbi request reprint Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study
    Isabelle M Germano
    Department of Neurosurgery, The Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Neurosurg 101:36-42. 2004
    ..Nevertheless, bilateral surgical procedures can be associated with frequent and severe complications. The aim in the present study was to assess the safety and efficacy of unilateral STN stimulation, and the need for a second procedure...
  55. ncbi request reprint The role of dopamine agonists in the treatment of early Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neurology 58:S33-41. 2002
    ....
  56. ncbi request reprint Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
    Clin Neuropharmacol 27:58-62. 2004
  57. ncbi request reprint Present and future directions in the management of motor complications in patients with advanced PD
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Neurology 61:S24-33. 2003
  58. pmc Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants
    Xianting Li
    Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, USA
    J Neurochem 103:238-47. 2007
    ..The distinctive levels of kinase/GTPase activity in brain LRRK2 may help explain LRRK2-associated neuronal functions or dysfunctions in the pathogenesis of PD...
  59. ncbi request reprint Neuroprotective agents in Parkinson's disease: clinical evidence and caveats
    Thomas D Hälbig
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Neurol Clin 22:S1-S17. 2004
  60. ncbi request reprint Sleepiness in Parkinson's disease: a controlled study
    Matthew A Brodsky
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 18:668-72. 2003
    ..These findings support the notion that sleep episodes while driving in PD patients are related to excess daytime sleepiness and dopaminergic load. Physicians should advise and treat patients accordingly...
  61. doi request reprint Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
    William J Marks
    Department of Neurology, University of California San Francisco, San Francisco, CA, USA
    Lancet Neurol 9:1164-72. 2010
    ..We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial...
  62. ncbi request reprint Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease
    Anthony H V Schapira
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, UCL, Queen Square, London, United Kingdom
    Ann Neurol 53:S149-57; discussion S157-9. 2003
  63. ncbi request reprint Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites
    Brian C Kramer
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Eur J Neurosci 19:280-6. 2004
    ..Our study suggests that limiting AA release and metabolism may provide benefit in conditions with an existing depletion of GSH, such as Parkinson's disease...
  64. ncbi request reprint Stem cell treatment for Parkinson's disease: an update for 2005
    Brian J Snyder
    Department of Neurosurgery, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Opin Neurol 18:376-85. 2005
    ..Development of cellular therapies offers the potential to provide more effective treatment for the disease without motor complications...
  65. doi request reprint Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
    William J Marks
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0138, USA
    Lancet Neurol 7:400-8. 2008
    ..The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin...
  66. ncbi request reprint Movement disorders and AIDS: a review
    Winona Tse
    Department of Neurology, Mount Sinai Medical Center, One Gustave L Levy Place, Box 1052, New York, NY 10029, USA
    Parkinsonism Relat Disord 10:323-34. 2004
    ..This review will also summarize current concepts regarding the pathophysiology of parkinsonism in HIV infection...
  67. ncbi request reprint Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  68. ncbi request reprint Altered proteasomal function in sporadic Parkinson's disease
    Kevin St P McNaught
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King s College, London Bridge, London SE1 1UL, UK
    Exp Neurol 179:38-46. 2003
    ..These findings suggest that failure of the ubiquitin-proteasome system to adequately clear unwanted proteins may underlie vulnerability and degeneration of the SNc in both sporadic and familial PD...
  69. ncbi request reprint The pathogenesis of cell death in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London, United Kingdom
    Neurology 66:S24-36. 2006
    ..This is an essential step to understanding pathogenesis and is critical to the development of comprehensive neuroprotective approaches to treatment...
  70. ncbi request reprint Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
    Fabrizio Stocchi
    Institute of Neurology and Neuromed, University La Sapienza, Viale dell Universita 30, 00185 Rome, Italy
    Brain 125:2058-66. 2002
    ..This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson's disease and reverse established motor fluctuations and dyskinesia...
  71. ncbi request reprint Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    ....
  72. ncbi request reprint Progress in clinical neurosciences: a forum on the early management of Parkinson's disease
    Anthony E Lang
    Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Canada
    Can J Neurol Sci 32:277-86. 2005
    ..This report summarizes presentations and discussion dealing with these issues from a one-day symposium involving Canadian Movement Disorders neurologists...
  73. ncbi request reprint Neuroprotection in Parkinson's disease: clinical trials
    Fabrizio Stocchi
    Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy
    Ann Neurol 53:S87-97; discussion S97-9. 2003
    ..Currently, this will most likely entail demonstrating that the drug provides benefit for PD patients for both imaging and clinical markers of disease progression...
  74. ncbi request reprint Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
    Matthew B Stern
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 19:916-23. 2004
    ..05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD...
  75. ncbi request reprint Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial
    Christopher G Goetz
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:179-86. 2007
    ..Sarizotan 2 mg/day is a safe agent in PD patients with dyskinesia. To test its role in abating dyskinesia, future studies should focus on this dose and will use the composite score of UPDRS Items 32+33 as the primary outcome...
  76. ncbi request reprint Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:41-7. 2007
    ....
  77. doi request reprint Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
    Jeffrey H Kordower
    Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, 1735 West Harrison Street, Chicago, Illinois 60612, USA
    Nat Med 14:504-6. 2008
    ..These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease...
  78. ncbi request reprint Continuous dopaminergic stimulation in early and advanced Parkinson's disease
    Fabrizio Stocchi
    Department of Neuroscience and IRCCS Neuromed Pozzilli IS, University La Sapienza, Rome, Italy
    Neurology 62:S56-63. 2004
    ..Therefore, the development of a simple treatment regimen using an oral formulation of levodopa to provide a more continuous dopaminergic stimulation will represent a significant advance in antiparkinsonian pharmacotherapy...
  79. ncbi request reprint Neuroprotection for Parkinson's disease: prospects and promises
    C Warren Olanow
    Ann Neurol 53:S1-2. 2003
  80. ncbi request reprint Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease
    C Warren Olanow
    Arch Neurol 62:1343-4. 2005

Research Grants8

  1. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..